Prostate Oncology

前列腺肿瘤项目是一个跨学科小组，由来自11个部门和4个学院的34名实验室、转化和临床研究人员组成，每年直接研究支持超过1300万美元，其中包括来自NCI的近400万美元。前列腺肿瘤项目，前身为泌尿肿瘤项目，在此拨款期间更名，以反映其在将前列腺癌的基础和临床发现转化为有效医疗解决方案方面的主要使命和关键力量。该项目包括前列腺孢子（最近更新），前列腺癌骨转移生物学PO1（最近更新），最近更新的国防部资助的前列腺癌临床试验联盟网站（DOD-PCCTC），前列腺早期疾病研究网络（EDRN）网站（新一期）和NIDDK培训补助金在泌尿学临床和转化研究培训（T32）。在此资助期间，34个项目成员发表了563份出版物，其中27.9%是项目内合作，31.3%是项目间合作。该项目致力于为基础和临床研究前列腺癌的研究人员创造和维持一个多学科的环境。前列腺肿瘤项目的科学目标是：1)研究导致前列腺癌恶性转化的遗传和表观遗传事件；2)表征促进前列腺癌生长或转移的肿瘤微环境的畸变；3)将基础科学发现转化为开发新的生物标志物和治疗泌尿系统癌症的方法。4)评估临床结果，指导治疗发展，同时降低癌症相关死亡率以及癌症和治疗相关发病率。在此资助期间进行的最具影响力的研究是项目成员发现前列腺癌中TMPRSS-ETS融合的开创性发现。前列腺肿瘤学项目的目标是了解前列腺癌的生物学，并利用这些信息开发前列腺癌的检测、诊断、预防和治疗的新工具。

The Prostate Oncology Program is an interdisciplinary group of 34 laboratory, translational and clinical researchers from 11 departments and four schools with over $13 million in annual direct research support including nearly $4 million from the NCI. The Prostate Oncology Program, formerly the Urologic Oncology Program, was renamed during this grant period to reflect Its primary mission and critical mass of strength In translating basic and clinical discoveries in prostate cancer into effective medical solutions. The program includes a Prostate SPORE (recently renewed), a PO1 on the Biology of Prostate Cancer Bone Metastasis (recently renewed), a recently renewed Department of Defense funded Prostate Cancer Clinical trials Consortium site (DOD-PCCTC), a prostate-focused Early Disease Research Network (EDRN) site (new this period) and a NIDDK training grant In Clinical and Translational Research Training in Urology (T32). Over this grant period the 34 program members published 563 publications of which 27,9% are intraprogrammatic and 31.3% are Inter-programmatic collaborations. The Program is committed to creating and sustaining a multidisciplinary environment for basic and clinical researchers studying prostate cancer. The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes with the purpose of guiding therapy development while reducing cancer-related mortality as well as cancer and therapy-associated morbidity. Among the most high Impact research conducted during this grant period were the seminal findings related to the discovery of TMPRSS-ETS fusions in prostate cancer by program members. The objective of the Prostate Oncology Program Is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, and treatment of prostate cancer.